מן הרשת 30.12.201912:07 Allergan Receives U.S. FDA Approval For Ubrelvy UBRELVY™ is the first and only oral CGRP receptor antagonist (gepant) FDA-approved for the acute treatment of migraine Allergan
מן הרשת 26.09.201917:33 Targeting CGRP and 5-HT1F Receptors for the Acute Therapy of Migraine A Literature Review David Moreno-Ajona, MD et al, Headache
מן הרשת 26.09.201917:30 Episodic and Chronic Migraine in Primary Care CM patients report higher levels of disability and less satisfaction with access to perceived needed medical advice and care Nathan P. Young et al., Headache
מן הרשת 26.09.201917:21 Neuromodulation for the Acute and Preventive Therapy of Migraine and Cluster Headache With improvements in our understanding of migraine and cluster headache pathophysiology, neuromodulation devices have been developed as safe and effective acute and preventive treatment options Rashmi B. Halker Singh, MD; Jessica Ailani, MD; Matthew S. Robbins, MD, Headache